Status:
UNKNOWN
High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
Almost 85% of new therapeutic molecules are abandoned before the clinical trial stage. Most of these failures currently concern cancer therapies. In order to optimize the development of these molecul...
Eligibility Criteria
Inclusion
- Patient whose age is ≥ 18 years old
- Patient with non-small cell bronchopulmonary cancer (NSCLC), at any stage, undergoing surgery in the Thoracic Surgery Department of the New Civil Hospital, Strasbourg.
- Patient who agreed to participate in this observational study.
- Patient affiliated to a social security system
Exclusion
- Refusal to participate in the study
- Known hepatitis, known HIV
- Subject under safeguard of justice
- Subject under guardianship or trusteeship
- Inability to give informed information about the subject (subject in an emergency situation, difficulties in understanding the subject)
- Pregnant Women
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04826913
Start Date
April 1 2021
End Date
April 1 2024
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67091